BIO Notebook: Califf On RWE, Industry Execs On Growing Therapeutic Areas, And More

Insights from Day Four of the BIO International Convention include FDA commissioner Califf on the state of real-world evidence and how it impacts IRA negotiations, Roche's interest in cardiovascular/metabolic assets, Merck's plans in immunology, and industry's rising interest in neuropsychiatry. 

BIO 2024 Day 4
• Source: Shutterstock

The US Food and Drug Administration is advising the Centers for Medicare and Medicaid Services on the types of real-world evidence research Medicare might want to look at as CMS works to come up with a maximum fair price for the drugs selected for negotiation under the Inflation Reduction Act.

CMS has said that when they negotiate under the IRA, Medicare is going to take into account real-world evidence, FDA...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from BIO

More from Conferences